NCT05388006View on ClinicalTrials.gov

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

February 22, 2027

Study Completion Date

February 22, 2027

Conditions
Chronic Lymphocytic LeukemiaRichter SyndromeSmall Lymphocytic Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Durvalumab

Given IV

DRUG

Venetoclax

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Positron Emission Tomography (PET)

Undergo PET/CT

PROCEDURE

Computed Tomography

Undergo PET/CT or CT

Trial Locations (3)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

63110

WITHDRAWN

Washington University School of Medicine, St Louis

94304

NOT_YET_RECRUITING

Stanford Cancer Institute Palo Alto, Palo Alto

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER